Plasmodium vivax is the most widespread human malaria, putting 2.5 billion people at risk of
infection. Its unique biological and epidemiological characteristics pose challenges to …

Plasmodium vivax is an important cause of malaria, associated with a significant public
health burden. Whilst enhanced malaria-control activities have successfully reduced the …

Malaria remains a major cause of morbidity and mortality in the tropics, with Plasmodium
falciparum responsible for the majority of the disease burden and P. vivax being the …

Background Chloroquine is the first-line treatment for Plasmodium vivax malaria in most
endemic countries, but resistance is increasing. Monitoring of antimalarial efficacy is …

Plasmodium vivax threatens almost 40% of the world's population, resulting in 132-391
million clinical infections each year. Most of these cases originate from South East Asia and …

Background Multidrug-resistant Plasmodium vivax (Pv) is widespread in eastern Indonesia,
and emerging elsewhere in Asia-Pacific and South America, but is generally regarded as a …

METHODS FOR SURVEILLANCE OF ANTIMALARIAL DRUG EFFICACY Page 1 METHODS FOR
SURVEILLANCE OF ANTIMALARIAL DRUG EFFICACY METHODS FOR SUR VEILLANCE OF …

New developments in Plasmodium vivax malaria: severe disease... : Current Opinion in
Infectious Diseases New developments in Plasmodium vivax malaria: severe disease and the …

Vivax malaria was historically described as 'benign tertian malaria'because individual
clinical episodes were less likely to cause severe illness than Plasmodium falciparum …

The gravity of the threat posed by vivax malaria to public health has been poorly
appreciated. The widely held misperception of Plasmodium vivax as being relatively …